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Luca BorradoridPurpose of review
There are few randomized controlled studies to guide the treatment of advanced cutaneous squamous cell
carcinoma. The existing treatments are mostly based on case reports and small case series. Here we
review recently available insights concerning the treatment of locally advanced and metastatic squamous
cell carcinoma, with a special emphasis on novel targeted therapy and immunotherapy.
Recent findings
Surgery and combination of chemotherapy and radiation therapy have been long considered the gold
standard options for advanced squamous cell carcinoma. The detection of clinically relevant driver
mutations has opened the door to the use of novel targeted therapies. Recent studies have shown that
aggressive cutaneous squamous cell carcinoma is characterized by a very high mutational background.
Furthermore, the importance of the defective immunosurveillance in the growth of cutaneous squamous cell
carcinoma and the critical role of programed cell death protein 1 and programmed death-ligand 1
interaction in skin tumor development provides a rationale for the use of immune checkpoint inhibitors.
Summary
Epidermal growth factor receptor inhibitors have shown to have satisfactory antitumor activity with
acceptable side-effect profile. However, their place in management of advanced cutaneous squamous cell
carcinoma alone or in combination with either radiation therapy and/or chemotherapy needs to be better
characterized. The available preliminary findings suggest that immune checkpoint inhibitors represent a
potentially valuable alternative in cutaneous aggressive squamous cell carcinoma, promising a further
expansion of their indication spectrum. Randomized controlled studies will allow us to better characterize
their practical value.
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Cutaneous squamous cell carcinomas (cSCC)
represent the second most-frequent skin cancer
[1]. cSCC are associated with significant morbidity
and are responsible for the majority of nonmela-
noma skin cancer (NMSC) deaths. Several risk fac-
tors for recurrence and metastasis have been
identified, such as large tumor diameter, poor histo-
logical differentiation and immunosuppression [2].
Definitive management of early or small cSCC
primarily relies on local therapies including topical
agents, thermal ablation, surgical resection or radi-
ation. However, in cases of locally advanced inop-
erable disease and metastatic disease, palliative
radiotherapy and/or classical chemotherapies can
offer modest clinical benefit. There is a critical need
for improved treatments in advanced cSCC patients.ht © 2017 Wolters Kluwe
rs Kluwer Health, Inc. All rights reseTwo general approaches that have made sub-
stantial improvements in systemic agents in oncol-
ogy have been the use of molecular targeted agents
and immune modulation. Epidermal growth factor
receptor (EGFR) and its family members are oftenr Health, Inc. All rights reserved.
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KEY POINTS
 The gold standard options for locally advanced
inoperable cutaneous squamous cell carcinoma have
been chemotherapy and/or radiation therapy, but the
overall responses are often poor and unsatisfactory.
 EGFR inhibitors have been increasingly used for
advanced cutaneous squamous cell carcinoma and
have shown antitumor activity.
 There is a strong biological rationale for the use of
immune checkpoint inhibitors, such as anti-PD-1
antibodies in advanced squamous cell carcinoma. The
preliminary results are encouraging but need to be
confirmed in controlled studies.
Melanoma and other skin neoplasmsoverexpressed or activated in human carcinomas
including cSCC and may contribute to enhance
uncontrolled proliferation. Anti-EGFR therapies
have clinical benefit alone or in combination with
chemotherapy and radiotherapy. The rat sarcoma
viral oncogene homolog–mitogen-activated protein
kinases signaling pathway, which is involved in reg-
ulating growth and proliferation of cSCC, represents
another new potential therapeutic target.
Current immune modulation strategies attempt
to generate a new antitumor response or to allow a
natural immune response to control tumor growth.
The development of cSCC is critically affected by a
defective immune surveillance with lack of tumor-
reactive T cells suggesting a role for immune control
of these tumors [3]. Recent studies have indicated
that cSCC is highly mutated, displaying a complex
genetic background [4
&&
]. Blocking either CTLA-4 or
programed cell death protein 1/programmed death-
ligand 1 (PD-1/PD-L1) on T cells generates antitu-
mor responses taking advantage of tumormutations
or ‘neoantigens’. Finally, certain types of cSCC
express PD-L1 and transgenic mice overexpressing
PD-L1 in the epidermis exhibit accelerated develop-
ment of cSCC [5]. In this context, immune check-
point antibodies that block the PD-1/PD-L1 pathway
and thereby increase the T-cell-specific immune
response represent a novel promising therapeutic
approach, which has been anecdotally used with
encouraging preliminary results.EPIDEMIOLOGY
Since the 1960s, the worldwide incidence of NMSC
has been constantly increasing. Fair-skin individuals
living in countries close to the equator and tropics
are the most commonly affected patients. In fact,
exposure to ultraviolet (UV) radiation and sunlight
represent the greatest risk factors for the Copyright © 2017 Wolters Kluwer 
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nature of UV radiation [6]. Australia has the highest
incidence in the world, with over 300000 patients
diagnosed per year. One study has estimated a diag-
nosis rate of 15–35 cSCCper 100000 people, with an
average increase of 2–4% per year [7]. In the United
States, up to 420000 new cases of cSCC have been
estimated to occur in 2012 [8]. Although only 5%
will become locally advanced, recur or metastasize,
this still represents a significant problem (Figs 1
and 2). Their overall fatality rate is estimated
between 1 and 5%. A large study reviewing 603
patients with metastatic cSCC found that 89% of
patients with distant metastasis died of their disease
at 5 years [9,10].AVAILABLE TREATMENTS: OVERVIEW
Therapeutic options for cSCC include surgery, radio-
therapy, chemotherapy, electrochemotherapy [11],
targeted pharmacologic therapy and/or immuno-
therapy. Treatment of cSCC depends on the involve-
ment of regional lymph nodes, distant metastasis
and/or inoperable metastatic disease [12]. However,
there is currently no clear standard of care for locally
advanced unresectable and metastatic cSCC.
Furthermore, the general condition of the patient,
patient’s age, associated comorbidities and immu-
nosuppression state are important variables that
should be considered for appropriate management
[13].
Current management of regional spread (drain-
ing lymph node basin) is surgical excision with
consideration of adjuvant radiation [14,15
&&
].
Surgery may be performed in patients with meta-
stasis when tumor characteristics (i.e. size, location
and number) allow for complete removal at or near
the primary tumor site [15
&&
]. However, improved
local disease control may be achieved when radio-
therapy is used in combination with surgery. Veness
et al. [16] assessed the results obtained in 167
patients over a 20-year period. Their findings
indicate that patients undergoing combined treat-
ment had a lower rate of locoregional recurrence as
well as a significantly better 5-year disease-free sur-
vival rate compared with surgery alone [16]. Hence,
radiotherapy should be discussed as an adjuvant
therapy [17], especially in the case of locally
advanced cSCC with high recurrence risk or meta-
static cSCC. However, in certain settings, it can also
be employed as a monotherapy [15
&&
].CHEMOTHERAPY AGENTS
Platin derivates, that is, cisplatin or carboplatin,
have been commonly used as the first-lineHealth, Inc. All rights reserved.
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FIGURE 1. Advanced cutaneous squamous cell carcinoma
developing on the left leg. Large ulcerated, partially
necrotic, local invasive and destructive lesions.
Drug therapy of advanced cutaneous squamous cell carcinoma Ribero et al.molecules for advanced unresectable or metastatic
cSCC but with limited clinical trial experience [18].
A recent single-center report suggested that patients
treated with cisplatin benefited with improved Copyright © 2017 Wolters Kluwe
FIGURE 2. Light microscopy studies of a biopsy specimen
obtained from an infiltrative growing cutaneous squamous
cell carcinoma. Atypical acanthotic epidermis with
hyperkeratosis and parakeratosis. Diffuse dermal infiltration
of the tumor originating in the epidermis with strands and
clusters of cells, focal horn pearl formation and dyskeratotic
cells. Several atypical keratinocytes with large eosinophilic
cytoplasm, mitoses and marked pleomorphism.
1040-8746 Copyright  2017 Wolters Kluwer Health, Inc. All rights reseresponse rates (RRs) and survival compared with
patients receiving other systemic agents. The study
was limited in size and was not randomized [19
&
].
Other molecules used for either advanced or
metastatic disease include 5-fluorouracil (5-FU),
bleomycin, methotrexate, adriamycin, taxanes,
gemcitabine or ifosfamide alone or in combination
[15
&&
]. RRs with single agents vary widely from 17 to
78% [20,21]. Platins and 5-FU are often used as
palliative treatment alone or in combination with
radiotherapy [22]. Polychemotherapies seem more
effective than monochemotherapy but result in
more side effects and poor tolerance. There is cur-
rently no standard treatment of metastatic disease.
Combinations of cisplatin with either 5-FU, doxor-
ubicin or bleomycin have demonstrated some
degree of efficacy, achieving complete responses
in some cases [23]. The current National Compre-
hensive Cancer Network guideline suggests cisplatin
either alone or in conjunction with 5-FU as first line,
but underlines the fact that available data are weak
and inconsistent and that newer options should be
considered [24].NOVEL TARGETED THERAPY: EPIDERMAL
GROWTH FACTOR RECEPTOR INHIBITORS
Advanced patient’s age, poor general condition or
medical comorbidities may preclude the use of con-
ventional chemotherapy [25,26]. In this context,
the identification of targetable driver mutations
important for cSCC progression opens the door to
new targeted therapies [27]. Previous studies have
shown that up to 80% of cSCC and 100% of meta-
static cSCC express EGFR [28]. The predictive role of
EGFR mutations and EGFR signaling in cSCC is still
debated [29,30]. The presence of activating
mutations in EGFR itself, elevated EGFR gene copy
number and/or aberrant expression of EGFR in
tumor cells have been shown to constitute predic-
tive markers of response to EGFR inhibition in
clinical trials [31]. Both antibody-based inhibitors
of the extracellular domain of EGFR and small mol-
ecule inhibitors of intrinsic tyrosine kinase activity
are available for targeted therapies.
Two monoclonal EGFR targeting antibiodies
have been evaluated in cSCC, cetuximab and pan-
itumumab. Cetuximab is a chimeric monoclonal
IgG1 antibody that prevents ligand-induced acti-
vation of EGFR and mediates a variety of antitumor
activities [32]. So far, the most important study in
cSCC is a phase II trial of Maubec et al. [33], in which
cetuximab was used as first-line treatment in 36
patients. Disease control could be achieved in 69%
of the intention-to-treat population at week 6. Two
complete remissions and eight partial remissionsr Health, Inc. All rights reserved.
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Melanoma and other skin neoplasmswere observed with acceptable skin toxicity. The
paucity of controlled trials and the low number of
patients described in retrospective case series and
single case reports limit the conclusions.
Neoadjuvant therapy with cetuximab alone or
in combination with platinum salt and 5-FU have
been proposed as a valid option for locally advanced
cSCC [34
&&
]. Cetuximab combined with radiother-
apy have also shown interesting results in terms of
response rate, disease-free survival and overall sur-
vival [35,36]. Data on combination therapies are
reported in Table 1. Panitumumab demonstrated
responses in locally advanced cSCC in a phase II
study [43]. This treatment has also been employed
with success in the case of anaphylaxis after cetux-
imab [44].
Oral agents targeting the EGFR pathway include
gefitinib and erlotinib. Gefitinib, which affects the
ATP-binding site of EGFR, inhibits autophosphory-
lation and receptor activation. A small phase II neo-
adjuvant study in patients undergoing resection or
radiotherapy demonstrated responses [complete
and partial responses (PRs) of 18.2 and 27.3%,
respectively] [45]. Treatment with gefitinib
appearedwell tolerated prior to surgery or combined
with radiotherapy, but the role in this context is
unclear. Similarly, erlotinib, another orally available
EGFR inhibitor, demonstrates responses in
advanced cSCC either alone [46] or in combination
with other therapies [47,48
&&
,49].
EGFR pathway inhibition is generally well tol-
erated but generally results in modest disease Copyright © 2017 Wolters Kluwer 
Table 1. Survey of combination therapies with cetuximab for adv
Reference Sample size Outcomes
Acevedo-Henao et al. [37] 36 Complete remiss
remission 17%
Okano et al. [38] 22 Partial remission
Knoedler et al. [39] 84 Partial remission
50%, median
Bossi et al. [40] 31 Well tolerated,
Matuschek et al. [41] 55 Maintenance fe
acceptable to
Strojan et al. [42] 30 OS 50%, diseas
OS, overall survival.
132 www.co-oncology.comcontrol in a fraction of patients measured inmonths
[30]. Resistance to EGFR inhibition develops rela-
tively rapidly. The latter may result from several
different mechanisms, including increased expres-
sion of EGFR, human epidermal growth factor recep-
tor 2 and 3, insulin-like growth factor 1 receptor and
tyrosine-protein kinase Met [50]. A mutation in
EGFR gene resulting in the substitution P753S and
activation of the EGFR kinase domain has been
regarded as a biomarker of resistance. Although
EGFR expression by tumor cells has been correlated
inversely with clinical outcome [51,52], the degree
of overexpression does not seem to correlate with
the effectiveness of EGFR inhibitors. Better under-
standing of the EGFR pathway is expected to provide
insights useful to design new trials.OTHER SIGNALING PATHWAYS AND
PHARMACOLOGICAL INHIBITORS
A recent gene set enrichment analysis has high-
lighted a key role for the MAPK pathway in cSCC
[53]. A significant subset of patients treated with
either the multikinase inhibitor sorafenib or the
BRAF V600E inhibitors vemurafenib and dabrafenib
rapidly develop cSCC [54]. Evidence exists indicat-
ing that these inhibitors result in a paradoxical
activation of the MAPK pathway, which in turn
cooperate with mutations in other key oncogenes
and tumor suppressors such as H-RAS and TP53 [55].
Hence, it is likely that inhibition of the MAPK path-
way provides a potential approach to treat cSCC.Health, Inc. All rights reserved.
anced cutaneous squamous cell carcinoma
Comments
ion 74%, partial
and OS 44.4%
Cetuximab induction followed by
weekly maintenance until week 7
together with radiotherapy
82% Cetuximab with concomitant boost
radiotherapy in treatment-naı¨ve
SCC for 7 weeks
11%, stable disease
OS 6.7 months
Cetuximab with docetaxel in
recurrent and/or metastatic SCC of
the head and neck
improved compliance Cetuximab as maintenance after
induction with chemotherapy
asible, with
xicity
Cetuximab maintenance (6 months)
after adjuvant concurrent
radiochemotherapy plus cetuximab
e-free survival 47% Induction chemotherapy (docetaxel,
cisplatin, 5-fluorouracil) followed
by radiotherapy and weekly
cisplatin and cetuximab
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CUTANEOUS SQUAMOUS CELL
CARCINOMAS DEVELOPMENT AND
IMMUNOTHERAPY WITH CHECKPOINTS
INHIBITORS
As withmost solid tumors, the role of tumor inflam-
mation appears critical to promoting the develop-
ment of cSCC and may control the growth of
established tumors [56]. cSCC is particularly pre-
valent in patients with chronic sun-exposure as well
as in immune suppressed patients, in whom there
is up to a 100-fold increased risk of developing
cSCC compared with the general population
[57,58,59
&
,60,61]. Chronic UV exposure results in
induction of suppressor T cells and depletion and
down-regulation of Langherans cells [62,63]. The
tumor microenvironment of cSCC is characterized
by a reduced number of peritumoral CD8þ cells [64]
and increased number of regulatory T cells. Presence
of tumor-associated macrophages, IL-10, transform-
ing growth-beta and vascular endothelial growth
factor all likely contribute to the immune dysfunc-
tion and tumor growth [65–67]. Finally, topical
application of imiquimod, which activates toll-like
receptors 7 on plasmacytoid dendritic cells, results
in secretion of proinflammatory cytokines [68,69]
and regression of squamous precancerous lesions
[70].
All these observations provide strong rationale
for the use of immunotherapy for advanced cSCC.
Specifically, checkpoints inhibitors, which are able Copyright © 2017 Wolters Kluwe
Table 2. Immunotherapy protocols encompassing immune ch
squamous cell carcinoma
Reference Cases Treatment Drugs
Day et al. [73&] Lung and liver
metastatic SCC
Third line Ipilimum
Winkler et al. [74&&] Lymph node
metastatic SCC
First line Pembro
Chang et al. [75&&] Locally advanced
SCC
Second line Pembro
Lipson et al. [76&&] Kidney-transplanted
patient
Second line Pembro
Metastatic SCC
Borradori et al. [77&&] Metastatic SCC Third line Pembro
Locally advanced
SCC
Fourth line Pembro
Locally advanced
SCC
Second line Nivolum
Metastatic SCC Fourth line Nivolum
PR, partial response.
1040-8746 Copyright  2017 Wolters Kluwer Health, Inc. All rights reseto activate a T-cell-specific immune response, have
shown antitumor activity in different malignancies
including malignant melanoma, non small-cell
lung cancer and head and neck SCCs [71,72]. How-
ever, there are almost no data regarding the use of
either the anti-CTLA4 antibody ipilimumab or anti-
PD-1 agents, such as nivolumab or pembrolizumab,
for cSCC [73
&
,74
&&
].
Since the first positive observation in a 72-year-
old patient with metastatic cSCC and melanoma, in
which four cycles of ipilimumab resulted in clinical
benefit and durable remission with a progression-
free survival of 8 months, there have been other
single case reports of adaptive immunotherapy in
the form of anti-PD-1 for advanced unresectable or
metastatic cSCC (Table 2). We have used anti-PD-1
inhibitors as rescue therapy in five cases with pro-
gressing advanced cutaneous squamous cell or
basosquamous carcinoma. Our heavily pretreated
patients with refractory tumors were given either
nivolumab or pembrolizumab and showed clinical
benefit including PRs and stable disease. Notewor-
thy in two cases with PR to anti-PD-1 inhibitors,
PD-1L expression failed to reliably predict response.
Anti-PD-1 therapy was well tolerated despite
multiple comorbidities, including HIV infection.
These findings are in line with the reported favor-
able side-effect profile of anti-PD-1 inhibitors. These
observations suggest that immune checkpoint
inhibitorsmay represent a promising new treatment
option for aggressive cSCC. Controlled studies arer Health, Inc. All rights reserved.
eckpoint antibodies for treatment of advanced cutaneous
Outcomes
Progression-free
survival
Significant adverse
events
ab PR 8 months Hypophysitis
lizumab PR 5 months None
lizumab PR 5 months Fatigue, weight loss
and arthralgias
lizumab PR 8 months Allograft rejection
lizumab PR 7 months Fatigue, brain
edema
lizumab Stable
disease
4 months None
ab PR 7 months None
ab PR 6 months Fatigue, weight loss,
hyponatremia
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Melanoma and other skin neoplasmsnow planned to define the role of checkpoint
modulation in management of nonmelanoma skin
cancers.CONCLUSION
Advanced cSCC remains a challenging disease with
poor clinical outcome. In cases of extensive disease
with local invasion and/or metastasis, surgery, anti-
neoplasmatic agents and/or radiotherapy are often
of limited value and efficacy. Comprehensive
genomic profiling with identification of genomic
targets and characterization of immunological path-
ways involved in cSCC development are currently
providing the rationale for the development of nov-
el targeted therapies and immunotherapies. The
final goal is to optimize clinical outcomes through
the effective personalization of treatment.
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